Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zihuan Liu

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Communications Engineering|February 5, 2026
High-velocity laser Doppler vibrometry measurements on an aluminum nitride bimorph wedge resonatorZihuan Liu, Xiaoyu Niu, Ehsan Vatankhah, et al.
Plos One|January 29, 2026
Modeling the beating degree of wheat straw biochemical mechanical pulp using multifactorial equationsZihuan Liu, Xiaoli Liang, Xiaoyun Zhang, et al.
American Journal of Hematology|April 8, 2026
Recurrent Genomic Alterations in BCRi-Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow-UpJennifer A Woyach, Relja Popovic, Emily L Rossi, et al.
Blood|August 12, 2024
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidineHartmut Döhner, Keith W Pratz, Courtney D DiNardo, et al.
Materials Today. Bio|April 21, 2026
Inhalable engineered probiotic outer membrane vesicles co-expressing multiple mpox antigens induce potent specific systemic and mucosal immune responsesXinting Fu, Wei Wang, Han Duan, et al.
Biomaterials|April 30, 2026
Engineered attenuated probiotic Escherichia coli oral vaccine provides effective protection against monkeypox virus by eliciting specific systemic and mucosal immunityHan Duan, Chenguang Shen, Xinting Fu, et al.
Blood Advances|February 24, 2026
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Blood Advances|November 21, 2025
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Communications Engineering|February 5, 2026
High-velocity laser Doppler vibrometry measurements on an aluminum nitride bimorph wedge resonatorZihuan Liu, Xiaoyu Niu, Ehsan Vatankhah, et al.
Plos One|January 29, 2026
Modeling the beating degree of wheat straw biochemical mechanical pulp using multifactorial equationsZihuan Liu, Xiaoli Liang, Xiaoyun Zhang, et al.
American Journal of Hematology|April 8, 2026
Recurrent Genomic Alterations in BCRi-Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow-UpJennifer A Woyach, Relja Popovic, Emily L Rossi, et al.
Blood|August 12, 2024
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidineHartmut Döhner, Keith W Pratz, Courtney D DiNardo, et al.
Materials Today. Bio|April 21, 2026
Inhalable engineered probiotic outer membrane vesicles co-expressing multiple mpox antigens induce potent specific systemic and mucosal immune responsesXinting Fu, Wei Wang, Han Duan, et al.
Biomaterials|April 30, 2026
Engineered attenuated probiotic Escherichia coli oral vaccine provides effective protection against monkeypox virus by eliciting specific systemic and mucosal immunityHan Duan, Chenguang Shen, Xinting Fu, et al.
Blood Advances|February 24, 2026
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Blood Advances|November 21, 2025
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Pageof 2